You are here
From patented antibodies to tumour-associated cell surface markers, we have a diverse portfolio of agents from pre-clinical to phase 1 clinical development available for collaborative development and/or licensing.
In collaboration with Universities of Oxford and Leicester our CRUK-AstraZeneca Antibody Alliance Laboratory has developed a first-in-class, inhibitory antibody specific for human ARG2.Read more
Licensing/collaborative opportunity around unique FcɣR-independent “super-agonistic” 4-IBB mABs containing a propriety hinge technology that promotes both CD8+ T cell activation and the depletion oRead more
A phase I trial of the anti-CD19 monoclonal antibody DI-B4 has demonstrated a highly positive safety profile, robust depletion of peripheral B cells and several partial tumour responses.Read more
We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.Read more